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ABSTRACT: Carbohydrates mediate a wide range of biological processes, and understanding these events and how they might
be influenced is a complex undertaking that requires access to pure glycoconjugates. The isolation of sufficient quantities of
carbohydrates and glycolipids from biological samples remains a significant challenge that has redirected efforts toward chemical
synthesis. However, progress toward complex glycoconjugate total synthesis has been slowed by the need for multiple protection
and deprotection steps owing to the large number of similarly reactive hydroxyls in carbohydrates. Two methodologies,
regioselective silyl exchange technology (ReSET) and glycosyl iodide glycosylation have now been integrated to streamline the
synthesis of the globo series trisaccharides (globotriaose and isoglobotriaose) and α-lactosylceramide (α-LacCer). These
glycoconjugates include tumor-associated carbohydrate antigens (TACAs) and immunostimulatory glycolipids that hold promise
as immunotherapeutics. Beyond the utility of the step-economy syntheses afforded by this synthetic platform, the studies also
reveal a unique electronic interplay between acetate and silyl ether protecting groups. Incorporation of acetates proximal to silyl
ethers attenuates their reactivity while reducing undesirable side reactions. This phenomenon can be used to fine-tune the
reactivity of silylated/acetylated sugar building blocks.
■ INTRODUCTION
For the past five decades, cancer has been one of the top 10
causes of death in the United States, and the incidence rate is
gradually increasing.1,2 Cancer treatments and therapeutics to
eradicate the disease are being intensively investigated in an
effort to improve quality of life for those who suffer.
Carbohydrate-based vaccine development is one promising
approach to this end.3−9 Cell membranes are decorated with
carbohydrates in the form of glycolipids and glycoproteins with
unique structures and aberrant glycosylation patterns that are
correlated with tumor progression and metastases.10−14
Vaccines based on the carbohydrate epitopes of these
glycoconjugates are promising therapeutic targets, as are the
more recently discovered bacterial derived glycolipids that
stimulate immune response. Limited access to sufficient
quantities of these biomolecules is a discovery roadblock
making practical synthesis of complex carbohydrates a top
priority in a recent National Academy of Sciences publication
on the future of glycoscience.15
One major class of mammalian glycosphingolipids (GSLs) is
the globo series tumor-associated carbohydrate antigens
(TACAs).3,4,10,14,16 Globotriaosyl ceramide (Gb3), isoglobo-
triaosyl ceramide (iGb3), Gb4, Gb5, and Globo H are the
prominent members of this class (Figure 1). All of these
biomolecules share a lactose core, which is diversified by
galactosylation at either the 3′ or 4′ hydroxyls giving rise to
iGb3 or Gb3, respectively. Gb3 in turn is the core structure
shared by Globo H and Gb5. Given the centrality of the Gb3
core, its synthesis has been the focus of numerous
investigations. Nicolaou and co-workers were the first to report
the total synthesis of Gb3, and their approach remains one of
the most efficient to date.17,18 A total of eleven steps from
commercially available lactose were required to prepare a
protected globotriaose that served as a donor for the ceramide
aglycon. Seven of those steps were focused on orthogonally
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protecting lactose for 4′-galactosylation. Similarly, all syntheses
of globotriaose/isoglobotraose that have engaged a lactosyl
acceptor have required between 6 and 12 steps to prepare the
disaccharide building block.16−29
While β-linked ceramides are known TACAs, bacterial
derived α-linked analogues also stimulate an immune response
and hold promise as vaccine adjuvants.30−33 Isolating these
glycolipids from their natural environments is a challenging
process that can lead to decomposition or even rearrangement
of the molecules of interest.34 The lipid composition of the
ceramide is also usually obtained as an inseparable and
noncharacterizable mixture. For these reasons, chemical
synthesis of α-linked ceramides is the primary source of pure
and homogeneous materials for immunological studies. To
meet this need, our group developed one-pot syntheses of
KRN7000, BbGL-II and α-GalCer (Figure 2) and their glucosyl
analogues,35,36 while the Wang37 and Savage24 groups have
reported syntheses of α-lactosylceramide, α-Gb3 and α-iGb3.
These novel “sugar-capped” CD1d ligands for natural killer T
(NKT) cells have been tested for their ability to stimulate
cytokine release. The results established that the α-linkage is
required for immune response and that the oligosaccharide
structures serve as immunomodulators. These findings and
biological evaluations of TACAs clearly point to an emerging
area of immunotherapeutic discovery based upon α- and β-
linked ceramides, and access to sufficient quantities of these
glycoconjugates is a critical need.
Recently, the concept of step-economy was introduced and
has subsequently been advocated among synthetic chem-
ists.38−41 Instead of the traditional linear synthesis or tour de
force total synthesis, considerations of semisynthesis, diversity-
oriented synthesis, function-oriented synthesis, and convergent
synthesis can lead to high efficiencies in the production of drug
leads. In applying this concept to glycoconjugate syntheses,
eliminating the need for multiple protection/deprotection steps
is an obvious starting point. Per-O-TMS protected mono-
saccharides have proven to be especially useful starting
materials for step-economy protecting group manipula-
tions.42−44 We have exploited these readily available com-
pounds in a process coined regioselective silyl exchange
technology (ReSET).45,46 In just two steps from free sugars,
a wide range of partially acetylated/silylated carbohydrates can
Figure 1. Globo series: A class of common TACAs.
Figure 2. Examples of immunostimulatory glycolipids.
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be prepared and readily transformed to either the correspond-
ing glycosyl donor or acceptor (Figure 3). The introduction of
electron-withdrawing acetate groups to silyl sugars affords
bifunctional modules that are more stable than their per-O-
TMS counterparts, yet highly reactive in glycosylation
reactions. The anomeric acetate can be converted into various
leaving groups including halides, thioethers and acetimidates.
Efforts reported herein have concentrated on integrating
glycosyl iodide glycosylation with a tandem ReSET strategy
to accomplish step-economy syntheses of globo series
trisaccharides and α-lactosylceramide. The dual methodology
platform expands the current organic synthesis toolbox and
provides new insight into the electronic interplay of acetate and
silyl ether functionalities and their influence upon chemical
reactivity.
■ RESULTS AND DISCUSSION
Tandem ReSET to Prepare Bifunctional Lactose
Modules. ReSET begins with per-O-silylated sugars, which
undergo selective exchange of silyl ethers for acetate protecting
groups. The reactions are typically run in pyridine with excess
acetic anhydride, and exchange is mediated by the addition of
acetic acid. Regiocontrol is correlated with acetic acid
stoichiometry and microwave reaction time. Typically, the
reactions afford a mixture of products, all of which are useful in
making a library of different analogues. For example, treating
per-O-silylated lactose with 3.0 equiv of AcOH for 1.25 h leads
to production of the di- and triacetylated compounds (1 and 2,
Scheme 1) in 20 and 53% yields, respectively, whereas
increasing the amount of acetic acid to 7 equiv forces the
production of compound 4 having only one silyl ether at the 4′
position and per-O-Ac lactose (5) after 3.75 h.46 Since the
lactosyl 3′ and 4′ positions are the major glycosylation sites for
globo series antigens, we attempted to establish conditions for
preparing the disilyl ether analogue (3), but that compound
could not be directly obtained in ReSET reactions of per-O-
silylated lactose under any of the conditions evaluated. Previous
studies in our lab indicated that proximal acetate groups
facilitate silyl exchange;46 thus, we reasoned that greater
regiocontrol might be achieved using compounds 1 and 2 in
a tandem process. To our delight, the reaction proceeded nicely
to afford the desired analogues, 3 and 4, in 31 and 25% yields,
respectively. With these partially acetylated building blocks (1−
4) in hand, focus shifted to employing them as either glycosyl
donors or acceptors in oligosaccharide and glycoconjugate
syntheses.
ReSET Products as Glycosyl Donors: α-Lactosylcer-
amide Synthesis. Previous attempts to form and utilize per-
O-TMS-lactosyl iodide led to complex reaction mixtures due to
glycosidic bond cleavage and silyl exchange.47 We later
discovered that C-6 acetates protect glycosidic linkages from
TMSI degradation.48,49 Consistent with these findings, we were
able to cleanly and quantitatively generate the lactosyl iodide
from both 1 and 2 (Scheme 2A).46 Synthetic ceramide (7)36,50
was selected as the acceptor in the glycosylation studies due to
its biological relevance. Iodide 6 was reconstituted in dry
benzene and cannulated into a mixture of 7, tetrabutylammo-
nium iodide (TBAI) and diisopropylethylamine (DIPEA). After
heating the reaction to 65 °C in anhydrous benzene overnight,
the reaction mixture was concentrated and subjected to acidic
methanolysis prior to per-O-acetylation for characterization
purposes (Scheme 2B). A mixture of the per-O-acetylated
isomers was isolated in 89% yield, and the ratio of primary
adduct (8) to secondary adduct (9) was 1.5 to 1.0, respectively,
as determined by anomeric proton integration values obtained
by 1H NMR.
The in situ anomerization process promoted by TBAI
resulted in the exclusive formation of α-linked glycosides;
Figure 3. Application of ReSET to generate bifunctional modules for oligosaccharide and glycoconjugate syntheses.
Scheme 1. Tandem ReSET Affords Differentially Protected Lactose Modules
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however, multiple flash column chromatography purifications
were required to separate 8 and 9. To alleviate this
complication, compound 10 was prepared by selective
desilylation of di-O-TMS ceramide42 according to a method
recently published by Cui and co-workers.51 Ceramide 10 was
then coupled with 6 under the TBAI-promoted conditions
(Scheme 2B). After acidic methanolysis and peracetylation,
compound 8 was the only glycosylation product isolated. The
glycosylation yield (61%) was slightly decreased compared to
the glycosylation result of ceramide 7 (89%), possibly due to
the result of increased steric hindrance from the secondary
TMS ether. Nevertheless, deacetylation of 8 using NaOMe/
MeOH led to fully deprotected α-lactosylceramide (11) in
quantitative yield.
The synthesis of α-lactosylceramide has several salient
features: (1) the glycosyl donor (6) can be prepared in three
steps and 72% overall from free lactose; (2) the lactosyl iodide
is reactive enough to couple with unprotected or partially
protected ceramides, yet the inter-residue glycosidic bond is
stable enough to survive glycosylation; (3) only the desired α-
linkage is obtained in good yield; (4) only TMS ether and
acetate protecting groups are utilized, allowing mild depro-
tection steps that are compatible with alkene and amide
functionality in the ceramide component. This methodology
nicely complements reactions of per-O-acetylated lactose,
which afford the β-anomer due to neighboring group
participation of the C-2 acetate.52
ReSET Products As Acceptors: Globo Series Trisac-
charide Syntheses. Having demonstrated glycosylation
Scheme 2. Synthesis of α-Lactosylceramide
Figure 4. Retrosynthetic analysis of globo series trisaccharides.
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efficiency with partially acetylated silyl donors, we set our sights
on exploiting these substrates as glycosyl acceptors. Chemical
syntheses of the Globo series TACAs involve the construction
of the crucial α-1,3 and α-1,4 glycosidic linkages. Yet a simple
first order disconnection of globotriaose and isoglobotriaose at
these linkages leads to 4′-OH acceptor 12, 3′,4′-di-OH
acceptor 13, or 3′-OH acceptor 14 (Figure 4), which are all
readily available from the tandem ReSET products 2, 3, and 4.
To reduce the glycosylation strategy to practice, compound 4
was treated with Dowex acidic resin in MeOH to give the 4′-
OH acceptor 12 in 90% yield (Scheme 3A). The long reaction
time (10 h) was consistent with earlier results in our lab
indicating that the rate of protodesilylation is attenuated with
increasing numbers of acetate protecting groups.46 In an
attempt to shorten the reaction time, we initially subjected 4 to
TBAF/AcOH, but the reaction led to unresolved trans-
acetylation products. However, a report from Ikawa and co-
workers53,54 encouraged us to explore the deprotection of silyl
ethers using Pd-catalyzed hydrogenolysis. Much to our delight,
after 30 min under 1 atm H2, 4 was transformed to 4′-OH
acceptor 12 in 91% yield. In a similar manner, either acidic
methanolysis or Pd-catalyzed hydrogenolysis was applied to 3,
leading to 3′,4′-di-OH compound 13 in 92 and 91% yields,
respectively (Scheme 3B). To confirm the deprotection was the
result of hydrogenolysis and not acidic catalysis, a control
experiment without the introduction of H2 gas was conducted.
No reaction was observed after 2 h, indicating that H2 gas is
required for the Pd-catalyzed deprotection.
In order to prepare 3′-OH acceptor 14, we looked to the
work of Lin and co-workers, who published a one-pot
procedure to selectively acetylate at the 4-position of galactose
via 3,4-orthoester formation followed by selective acidic
hydrolysis.55 The procedure showed excellent results when
applied to monosaccharides but not oligosaccharides, presum-
ably because of solubility issues.56 An adapted version of the
methodology was applied to ReSET products 2 and 3 (Scheme
4). Compound 2 was first subjected to Pd-catalyzed hydro-
genolysis and then concentrated to dryness. The resulting
residue was reacted with trimethyl orthoacetate in the presence
of catalytic camphor sulfonic acid (CSA) to form the cyclic
orthoester at the 3′ and 4′ positions. After peracetylation, the
orthoester was selectively hydrolyzed affording the 3′-OH
acceptor (14) in almost quantitative yield. The four-step
procedure was carried out in less than 3 h, and only one flash
column chromatography purification was needed to obtain the
target molecule. The consecutive hydrogenolysis−orthoester
formation−acidic hydrolysis protocol was also applied to di-O-
TMS compound 3, leading to the same 3′-OH acceptor 14 in
almost quantitative yield (Scheme 4).
With all the acceptors (12−14) in hand, we next examined
the glycosylation reactions to form the globo series
trisaccharides (Table 1). Wishing to achieve efficient α-
galactosidation of the 4′-OH acceptor (12), we first tried
using per-O-TMS galactosyl iodide promoted by TBAI in situ
anomerization,35,36 but the major product obtained was
silylated acceptor. We previously observed similar trans-
silylation complications, especially in cases where the acceptor
is hindered or unreactive.57,58 However, the per-O-benzyl
galactosyl iodide derived from anomeric acetate 1559 was
reactive when activated with AgOTf, and the presence of benzyl
protecting groups conveniently allowed UV monitoring of the
reaction progress. Importantly, only the desired α-1,4 linkage
was obtained, which simplified the purification (Table 1, entry
1). The same reaction conditions with 1.5 and 2.5 equiv of
Scheme 3. Synthesis of Acceptors 12 and 13
Scheme 4. Synthesis of 3′-OH Acceptor 14
The Journal of Organic Chemistry Article
dx.doi.org/10.1021/jo402736g | J. Org. Chem. 2014, 79, 1736−17481740
iodide were applied to the glycosylation reaction with acceptor
13 to examine the relative reactivity of the two hydroxyl groups.
When 1.5 equiv of iodide was used, the desired protected
isoglobotraose (17) was obtained, albeit in a lower yield of 44%
(Table 1, entry 2). When 2.5 equiv of iodide was added, not
only was 17 obtained in 26% yield, but also the digalactosylated
product (18) was obtained in 31% yield (Table 1, entry 3).
To avoid over-galactosylation, the 3′-OH acceptor 14 was
introduced. In this case, the desired product (19) was obtained
in 58% yield (Table 1, entry 4). Side reactions, which we
attributed to acyl migration, were also observed on the TLC
plate. To minimize this possibility, an acid scavenger
(tetramethylurea, TMU)60 was added to the AgOTf-promoted
glycosylation (Table 1, entry 5). The neutralized glycosylation
procedure required higher temperature and longer time to
complete; however, the target molecule (19) was obtained in
75% yield, indicating that the side reactions could be
suppressed by the addition of weak base.
Debenzylation of compound 16 followed by reacetylation led
to per-O-Ac globotriaose 20 in 95% yield (Scheme 5). Storing
the trisaccharide in the peracetylated form was desired to
increase stability. Moreover, the 1H NMR signals of compound
20 were better resolved than the benzylated counterpart (16),
making compound characterization and quality control more
reliable. Acetate protecting groups are also preferred when
generating the glycosyl iodide of the trisaccharides. When
compound 16 was treated with TMSI, the reaction became
messy and glycosidic bond cleavage products were observed in
crude MS analyses; another example of electron donating
protecting groups rendering the glycosidic linkage susceptible
to cleavage. In contrast, peracetylated 20 readily transformed to
the corresponding iodide (22) in situ, and subsequent reaction
leads to β-linked glycoconjugates.
Global deprotection of 16 continued with Pd-catalyzed
hydrogenolysis followed by deacetylation yielding globotriaose
(21) in nearly quantitative yield (Scheme 5). The total
synthesis of globotriaose required only four steps from free
lactose to form the globotriaose scaffold, and two more
consecutive protecting group manipulations (total six steps) to
the natural product globotriaose (21).
In 1988, Nicolaou and co-workers published the first
synthesis of Gb3, which is arguably the most efficient synthesis
until now.17 The approach required seven steps to prepare a
selectively protected 4′-OH acceptor, which was glycosylated
with per-O-Bn galactosyl fluoride under the activation of AgCl4
and SnCl2. During the process, seven protecting groups (OAc,
Table 1. Glycosyl Iodide Glycosylation Gave Gb3 and iGb3 Trisaccharide Scaffolds
*Condition: 3.0 equiv of AgOTf, 3.0 equiv of tetramethylurea (TMU), 4 Å MS, CH2Cl2, −30 °C to rt, 24 h.
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OBn, OBz, OPiv, SPh, F, and benzylidene) were utilized. In
contrast, the simplified RESET/glycosyl iodide synthetic
platform involves only three steps to prepare the 4′-OH
glycosyl acceptor and arrives at the globotriaose scaffold in four
steps. Moreover, the glycosyl iodides react under neutral
conditions avoiding toxic tin reagents as the promoter for α-1,4
glycosylation.
Compounds 17 and 19 could be transformed to per-O-Ac
isoglobotriaose (23) in 85% yield by hydrogenolysis and
peracetylation (Scheme 6). In 2009, Castillon and co-workers
published an efficient TBAI/AW-300 MS-promoted synthesis
of iGb3 using per-O-Ac isoglobotriaose iodide and stannylcer-
amide.61 The group purchased isoglobotriaose and peracety-
lated it prior to generating the iodide. In the total synthesis
approach to iGb3 reported here, both 23 and the in situ
generated iodide intercept the Castillon synthesis, providing a
formal synthesis of iGb3.
Among the published syntheses of isoglobotriaose scaffold
using 3′,4′-di-OH acceptors, galactosylation typically suffers
from low yields and poor stereoselectivity. Moreover, the 3′,4′-
di-OH acceptors require at least six or seven steps to prepare
from free lactose. When using acetylated galactosyl bromide24
and trichloroacetimidate26 donors, the glycosylation yields
ranged from 28 to 31% with inseparable α-1,3 and β-1,3
isomers. In order to eliminate side reactions and increase donor
reactivity, both Ogawa25 and Schmidt27 have introduced O-
benzyl-protected galactosyl thiomethyl and trichloroacetimidate
donors. These reactive donors provided increased yields but did
not prevent the formation of β-linked isomers. In contrast, O-
benzyl protected galactosyl iodide (Table 1, entries 2 and 3)
readily reacts with acceptors 12, 13, and 14 to afford the α-
linked products exclusively and in yields ranging from 44 to
75%.
Selectively protected 3′-OH acceptors generally afford better
yields than 3′,4′-di-OH acceptors, since there is no competition
between the two hydroxyl groups. However, 6−8 steps were
required in order to prepare the 3′-OH acceptors. The
protecting group manipulations involved OAc, OBn, OPiv,
OPMB, and SPh groups, and the preparation took days to
complete.28,29 In comparison, the ReSET approach (Table 1,
entry 4 and 5) required only three protecting groups (OBn,
OAc, and OTMS) and 21 h to synthesize acceptor 14. The
optimized glycosylation of compound 14 reached 75% yield
when coupled with per-O-Bn galactosyl iodide.
■ CONCLUSION
The combined ReSET/glycosyl iodide glycosylation strategy
provides a step-economy platform for glycoconjugate synthesis
that centers on the conversion of per-O-TMS-lactose into
selectively protected modules with differential reactivities.62
The orthogonally protected intermediates can be transformed
into reactive glycosyl iodides in situ and coupled with
Scheme 5. Six-Step Synthesis of Globotriaose from Free Lactose
Scheme 6. Formal Synthesis of iGb3 from Compound 17
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unprotected or partially protected ceramides with high
stereoselectivity in good yields. The marriage of these powerful
platforms results in the exclusive formation of alpha-linked
glycosides, which leads to increased efficiencies during the
purification process. The bifunctional nature of these modules
can be further exploited upon removal of the TMS groups
yielding glycosyl acceptors ready for sugar chain elongation.
When introduced into glycosylation reactions, the correspond-
ing globo series tumor-associated carbohydrate antigens can be
obtained in respectable yields. The TACA syntheses require
only three protecting groups (OAc, OBn, and OTMS), which
significantly reduces the number of protection/deprotection
steps, not only in preparing the glycosyl acceptors, but also by
direct activation of the anomeric acetate or silyl ether to the
glycosyl iodide. These combined features characterize a
versatile synthetic platform for the rapid assembly of bio-
logically relevant glycolipids.
Beyond the time and step efficiencies of these method-
ologies, a unique interplay between acetate and silyl ether
protecting groups is revealed. The acetate protecting groups
help suppress side reactions such as silyl migration and inter-
residue glycosidic bond cleavage during TMSI-promoted iodide
formation. Similarly, we find that proximal acetates significantly
alter the reactivity of silyl ethers toward protodesilylation. This
phenomenon is clearly evidenced in the acidic methanolysis of
4′-OTMS acetylated lactose (4), which took twice as long as
analogue 3 having one less acetate, i.e., 3′,4′-di-OTMS
acetylated lactose. We attribute the reactivity attenuation to
acetate electron withdrawing effects, which inductively reduce
the basicity of the ether and acetal oxygen atoms. Exquisite
control is afforded by acetate incorporation, as shown in the
contrasting behavior of per-O-silylated lactose and 6,6′-di-O-
Ac-per-O-silyllactose (1) under the action of TMSI. Di- and
trisaccharide substrates having no acetates undergo inter-
residue glycosidic bond cleavage, whereas incorporation of only
two acetate groups at the C-6 positions directs reactivity toward
the reducing end acetal resulting in the quantitative generation
of the corresponding glycosyl iodides. These findings offer
opportunities in systems removed from carbohydrate substrates
where one could capitalize on the concept of attenuating ether
reactivity by the inductive effects of proximal protecting groups.
■ EXPERIMENTAL SECTION
Procedure for Tandem Regioselective Silyl Exchange
(ReSET) of Per-O-TMS Lactose (Scheme 1). In a 10 mL microwave
reactor vessel with a dry stir bar, per-O-TMS lactose (500 mg, 0.54
mmol) was dissolved in anhydrous benzene (3 mL). The solvent was
removed under rotary evaporation with argon backfilling. The
azeotropic distillation was repeated two additional times to dryness
affording viscous syrup. To the reaction flask was added anhydrous
pyridine (2.0 mL/per mmol TMS sugar: 1.1 mL), Ac2O (1.5 mL/per
mmol TMS sugar: 8.1 mL), and AcOH (93 μL, 1.62 mmol, 3.0 equiv).
The reaction vessel was subjected to microwave irradiation (standard
mode, 100 W, 125 °C, ∼40 psi) for 1.25 h. Once TLC showed the
reaction was complete, the reaction mixture was transferred into a 50
mL round-bottom flask, where it was azeotroped with copious
amounts of anhydrous benzene to remove excess reagents and solvent.
The crude mixture was immediately purified by gradient flash column
chromatography (EA/Hex/NEt3 = 5:85:10 to 14:85:1 to 29:70:1) to
afford compound 1 (93 mg, 20%) and 2 (239 mg, 53%). Later on,
compound 1 and 2 were combined. A mixture of compound 1 and 2
(194 mg, ∼0.23 mmol: calculated on the basis of compound 2′s
molecular weight; same as the following) was then treated with dry
pyridine (0.35 mL), Ac2O (0.46 mL) and AcOH (40 μL, 0.69 mmol,
∼3.0 equiv), followed by microwave irradiation (standard mode, 100
W, 125 °C, ∼40 psi) for 1.5 h. After the starting material was
completely consumed, the reaction was azeotroped with dry benzene
to remove excess reagents and solvent. The resulting residue was
immediately purified by gradient flash column chromatography (EA/
Hex = 40:60 to 60:40) to afford compound 3 (54 mg, ∼31%),
compound 4 (41 mg, ∼25%) and compound 5 (42 mg, ∼26%) as
white foams.
(2,6-Di-O-acetyl-3,4-O-ditrimethylsilyl-β-D-galactopyranosyl)-(1−
4)-O-(1,2,3,6-tetra-O-acetyl)-D-glucopyranoside (3). Compound 3
(54 mg, ∼31%) was obtained from consecutive ReSET of per-O-TMS
lactose (see ReSET procedure for reaction and purification
conditions). The product consisted of inseparable α/β anomeric
acetates and the major β-anomer is reported: TLC (EA/Hex = 40:60)
Rf 0.38;
1H NMR (800 MHz, CDCl3) δ 5.66 (d, J = 8.2 Hz, 1H, H-1),
5.21 (appt. t, J = 9.3 Hz, 1H, H-3), 5.06−5.00 (m, 2H, H-2, H-2′),
4.40 (dd, J = 12.0, 1.7 Hz, 1H, H-6a), 4.28 (d, J = 7.9 Hz, 1H, H-1′),
4.19−4.14 (m, 2H, H-6b, H-6′a), 4.10 (dd, J = 11.0, 6.6 Hz, 1H, H-
6′b), 3.79 (appt. t, J = 9.3 Hz, 1H, H-4), 3.77−3.72 (m, 2H, H-4′, H-
5), 3.57 (appt. t, J = 6.6 Hz, 1H, H-5′), 3.53 (dd, J = 9.8, 2.7 Hz, 1H,
H3′), 2.11 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.04 (s,
3H), 2.02 (s, 3H), 0.12 (s, 9H), 0.11 (s, 9H); 13C NMR (200 MHz,
CDCl3) δ 170.6, 170.5, 169.8, 169.7, 168.9, 168.89, 101.1, 91.6, 74.9,
73.6, 72.9, 72.6, 72.4, 71.6, 71.1, 70.5, 62.5, 62.1, 21.1, 20.84, 20.82,
20.7, 20.6, 0.4, 0.2; HRMS (ESI-ion trap) m/z calcd for [C30H50O17Si2
+ NH4
+] 756.2925, found 756.2947.
General Procedure for α-Lactosylceramide Synthesis
(Scheme 2). In an oven-dried NMR tube, compound 2 (59 mg,
0.07 mmol) was added and dissolved in dry benzene-d6 (0.7 mL).
After TMSI (12 μL, 0.08 mmol) was introduced to the reaction vessel,
the reaction was kept and 0 °C and gradually warmed to rt over 4−5 h.
The reaction was monitored by proton NMR until the corresponding
iodide (6) formed in situ. Next, compound 6 was transferred to a 25
mL pear-shape bottle, azeotroped with dry benzene (3 mL × 3) and
dried under a high vacuum for 1 h to afford the iodide as a light yellow
foam. Note: The iodide is highly reactive and moisture sensitive. Column
chromatography or aqueous workup should be avoided. The compound 6
was next dissolved in dry benzene (2 mL) and kept under Ar. In a
separate round-bottom flask, ceramide 7 (20 mg, 0.035 mmol), TBAI
(52 mg, 0.14 mmol), DIPEA (25 mL, 0.14 mmol) and activated 4 Å
molecular sieves (80 mg) were dissolved in dry bezene (2 mL) and
stirred at rt under Ar. The iodide solution was transferred to the
glycosyl acceptor solution via cannula dropwisely over 3 min at rt.
Once transferred, the reaction mixture was gently heated to 65 °C
overnight. Next, the reaction mixture was cooled to rt, filtered through
a short Celite pad and concentrated under reduced pressure. The
resulting residue was dissolved in MeOH (5 mL) and stirred with the
Dowex acidic resin (pH = 2−3) at rt. After 2 h, the resin was filtered,
and the solvent was evaporated under reduced pressure to afford a
viscous orange oil. The resulting oil was then dissolved in CH2Cl2 (1
mL) under Ar. To the solution was then added Ac2O (0.8 mL), NEt3
(1.2 mL) and catalytic DMAP (∼2 mg), and the mixture was stirred at
rt overnight. Next, the reaction mixture was concentrated under
reduced pressure and was purified using flash column chromatography
(EA/Hex = 50:50) to afford a mixture of isomers (compounds 8 and
9) (39 mg, 89%) as a white foam. The mixture could be further
purified by gradient flash column chromatography (EA/Hex = 40:60
to 60:40) to separate both isomers for characterization purpose.
Mono-O-TMS protected ceramide 10 (19 mg, 0.03 mmol) could also
be applied to the above reaction conditions but using 50 °C in the
glycosylation step. Followed by desilylation and reacetylation,
compound 8 (22 mg, 61%) was obtained as the only isomer.
(2S,3R,4E)-3-O-Acetyl-1-O-(α-per-O-acetyl-D-lactopyranosyl)-2-
(N-octadecanosylamino)octadec-4-ene-1,3-diol (8). Compound 8
was obtained either from glycosyl iodide glycosylation using iodide 6,
and ceramide 7 or ceramide 10 (see general procedure for α-
lactosylceramide synthesis for reaction and purification conditions):
TLC (EA/Hex = 1/1) Rf 0.43; [α]
24
D +16.5 (c 0.26, CHCl3);
1H
NMR (800 MHz, C6D6) δ 5.88 (appt. t, J = 9.5 Hz, 1H, H-3), 5.86−
5.82 (m, 1H, alkene H-e), 5.55 (appt. t, J = 7.9 Hz, 1H, H-c), 5.52−
5.47 (m, 3H, alkene H-d, H-2′, H-4′), 5.44 (d, J = 9.2 Hz, 1H, NH),
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5.14 (dd, J = 10.4, 3.4 Hz, 1H, H-3′), 5.10 (dd, J = 9.5, 3.7 Hz, 1H, H-
2), 5.05 (d, J = 3.7 Hz, 1H, H-1), 4.73 (d, J = 10.4 Hz, 1H, H-6a),
4.63−4.58 (m, 1H, H-b), 4.39 (d, J = 7.8 Hz, 1H, H-1′), 4.22 (dd, J =
11.7, 6.4 Hz, 1H, H-6b), 4.14 (dd, J = 11.1, 6.6 Hz, 1H, H-6′a), 4.11−
4.05 (m, 2H, H-5, H-6′b), 3.77 (dd, J = 10.7, 3.2 Hz, 1H, H-a), 3.67
(appt. t, J = 9.5 Hz, 1H, H-4), 3.50 (appt. t, J = 6.6 Hz, 1H, H-5′), 3.44
(dd, J = 10.7, 4.0 Hz, 1H, H-a′), 2.02 (s, 3H), 2.01 (s, 3H), 2.00 (s,
3H), 1.95 (s, 3H), 1.87 (s, 3H), 1.74 (s, 3H), 1.69 (s, 3H), 1.66 (s,
3H), 1.55 (s, 3H), 1.35−1.26 (m, 52H, alkyl chain), 0.93−0.91 (m,
6H, terminal Me × 2); 13C NMR (200 MHz, C6D6) δ 172.3, 170.3,
170.2, 170.1, 169.9, 169.8, 169.4, 169.2, 169.1, 137.3, 128.4, 128.3,
128.2, 128.1, 128.0, 127.9, 126.1, 101.6, 96.8, 77.2, 73.1, 71.6, 71.5,
70.9, 70.7, 69.7, 69.2, 67.4, 67.0, 62.6, 61.1, 51.3, 36.5, 32.8, 32.38,
32.37, 30.3, 30.28, 30.26, 30.25, 30.24, 30.19, 30.18, 30.0, 29.88, 29.87,
29.77, 29.72, 29.4, 26.1, 23.2, 20.9, 20.7, 20.6, 20.5, 20.49, 20.2, 20.16,
19.8, 14.4; HRMS (ESI-ion trap) m/z calcd for [C64H107NO21 + Na
+]
1248.7228, found 1248.7227.
(2S,3R,4E)-1-O-Acetyl-3-O-(α-per-O-acetyl-D-lactopyranosyl)-2-
(N-octadecanosylamino)octadec-4-ene-1,3-diol (9). Compound 9
was obtained from the glycosyl iodide glycosylation using iodide 6 and
ceramide 7 (see general procedure for α-lactosylceramide synthesis for
reaction and purification conditions): TLC (EA/Hex = 1/1) Rf 0.40;
[α]24D +21.6 (c 0.47, CHCl3);
1H NMR (800 MHz, C6D6) δ 5.88
(appt. t, J = 9.5 Hz, 1H, H-3), 5.69 (d, J = 8.6 Hz, 1H, NH), 5.60 (ddd,
J = 18.6, 9.1, 3.4 Hz, 1H, alkene H-e), 5.55−5.52 (m, 1H, H-2′), 5.49
(d, J = 3.5 Hz, 1H, H-4′), 5.38 (dd, J = 15.5, 8.0 Hz, 1H, alkene H-d),
5.21 (d, J = 3.7 Hz, 1H, H-1), 5.15 (dd, J = 10.5, 3.5 Hz, 1H, H-3′),
5.06 (dd, J = 10.2, 3.7 Hz, 1H, H-2), 4.67 (dd, J = 11.8, 2.0 Hz, 1H, H-
6a), 4.51 (d, J = 7.9 Hz, 1H, H-1′), 4.42 (ddd, J = 8.9, 7.4, 4.6 Hz, 1H,
H-b), 4.36 (dd, J = 11.6, 6.0 Hz, 1H, H-a), 4.31 (dd, J = 11.9, 4.6 Hz,
1H, H-6b), 4.22−4.06 (m, 5H, H-5, H-6′ab, H-c, H-a′), 3.87−3.83 (m,
1H, H-4), 3.48 (appt. t, J = 7.0 Hz, 1H, H-5′), 2.01 (s, 3H), 1.98 (s,
3H), 1.91 (s, 3H), 1.83 (s, 3H), 1.78 (s, 1H), 1.74 (s, 3H), 1.64 (s,
3H), 1.53 (s, 3H), 1.43−1.22 (m, 52H, alkyl chain), 0.95−0.91 (m,
6H, terminal Me × 2); 13C NMR (200 MHz, C6D6) δ 171.8, 171.1,
170.4, 170.1, 169.9, 169.8, 169.7, 169.2, 168.9, 136.1, 127.3, 101.6,
97.2, 81.8, 76.9, 72.2, 71.6, 70.9, 70.8, 69.9, 69.3, 66.9, 63.0, 62.2, 60.9,
52.6, 36.8, 32.6, 32.38, 32.37, 30.3, 30.27, 30.25, 30.23, 30.20, 30.18,
30.1, 30.0, 29.97, 29.9, 29.87, 29.80, 29.5, 26.0, 23.1, 20.9, 20.7, 20.6,
20.5, 20.4, 20.2, 20.1, 19.8, 14.4; HRMS (ESI-ion trap) m/z calcd for
[C64H107NO21 + Na
+] 1248.7228, found 1248.7272.
(2S,3R,4E)-3-O-Trimethylsilyl-2-(N-octadecanosylamino)octadec-
4-ene-1,3-diol (10). To a 0 °C CH2Cl2 (3 mL) solution of compound
7 (150 mg, 0.27 mmol) was added 1,1,1,3,3,3-hexamethyldisilazane
(HMDS, 121 μL, 0.58 mmol) and TMSOTf (∼5 μL, 0.03 mmol), and
the mixture was gradually warmed to rt in 2 h (based on Wang’s
method).63 The reaction mixture was then diluted with EA/Hex (v/v
=1:1, 20 mL) and washed with water and brine. The organic layer was
dried over Na2SO4 and concentrated under reduce pressure to afford
per-O-TMS ceramide (179 mg, 95%) as a white powder. Per-O-TMS
ceramide (179 mg, 0.25 mmol) was dissolved in a well-stirred
CH2Cl2/MeOH (v/v = 1:1, 3 mL) solution. To the solution was
added NH4OAc (38 mg, 0.5 mmol), and the reaction was stirred at rt
for 10 h. The reaction mixture was concentrated and purified using
flash column chromatography (EA/Hex = 1/4 to 1/2) to afford mono-
O-TMS-protected ceramide 10 (91 mg, 58%) as a white amorphous
solid: TLC (EA/Hex = 1/5) Rf 0.20; [α]
24
D −15.0 (c 0.02, MeOH);
1H NMR (600 MHz, C6D6) δ 5.94 (d, J = 7.4 Hz, 1H, NH), 5.63
(ddd, J = 7.9, 6.8, 3.4 Hz, 1H, H-5), 5.42 (dd, J = 15.4, 6.1 Hz, 1H, H-
4), 4.56−4.49 (m, 1H, H-3), 4.06 (d, J = 11.5 Hz, 1H, H-1a), 3.97 (dt,
J = 7.2, 3.5 Hz, 1H, H-2), 3.65−3.55 (m, 1H, H-1b), 3.06 (d, J = 7.0
Hz, 1H, OH), 1.96−1.93 (m, 4H, H-6ab, H-2′ab), 1.70 (dd, J = 14.1,
7.0 Hz, 2H, H-7ab), 1.46−1.17 (m, 52H, alkyl chain), 0.97−0.85 (m,
6H, terminal Me × 2), 0.14−0.03 (s, 9H, TMS); 13C NMR (150 MHz,
C6D6) δ 172.3, 133.1, 130.2, 75.7, 62.5, 55.2, 36.7, 32.6, 32.4, 30.24,
30.20, 30.16, 30.1, 29.98, 29.92, 29.9, 29.8, 29.7, 29.6, 26.0, 23.1, 14.4,
0.2; HRMS (ESI-ion trap) m/z calcd for [C39H79NO3Si + H
+]
638.5902, found 638.5930.
(2S ,3R,4E)-3-O-Acety l -1-O-(α -D- lactopyranosyl ) -2- (N-
octadecanosylamino)octadec-4-ene-1,3-diol (11). Compound 8 (17
mg, 0.012 mmol) was dissolved in dry MeOH (2 mL) and treated with
25% NaOMe in MeOH solution (∼5 μL) at rt. After 1 h, Dowex acidic
resin was added to the reaction mixture until pH = 7. The mixture was
then filtered through a short Celite plug and concentrated under
reduced pressure to afford compound 11 (15 mg, >98%) as a white
powder: TLC (EA/MeOH/H2O = 7:2:1) Rf 0.77; [α]
24
D +2.7 (c 0.40,
MeOH); 1H NMR (800 MHz, pyridine-d5) δ 8.48 (d, J = 8.5 Hz, 1H,
NH), 6.01−5.99 (m, 2H, alkene H × 2), 5.37 (d, J = 3.7 Hz, 1H, H-1),
5.09 (d, J = 7.8 Hz, 1H, H-1′), 4.88−4.85 (m, 1H, H-c), 4.82−4.80
(m, 1H, H-b), 4.57−4.39 (m, 8H, H-3, H-2′, H-4′, H-6ab, H-6′ab, H-
a), 4.37−4.34 (m, 1H, H-5), 4.32−4.30 (m, 1H, H-a′), 4.25 (appt. t, J
= 9.3 Hz, H-4), 4.16−4.14 (m, 2H, H-3′, H-5′), 4.13 (dd, J = 3.7, 9.3
Hz, 1H, H-2), 2.44 (appt. t, J = 7.5, 2H, H-g, H-g′), 2.11−2.08 (m, 2H,
H-f, H-f′), 1.88−1.81 (m, 2H, H-h, H-h′), 1.39−1.22 (m, 52H, alkyl
chain), 0.90−0.87 (m, 6H, terminal Me × 2); 13C NMR (200 MHz,
pyridine-d5) δ 174.0, 133.0, 132.5, 106.3, 101.7, 83.1, 77.7, 75.7, 74.0,
73.9, 73.2, 73.0, 72.9, 70.6, 69.6, 62.8, 62.6, 55.6, 37.3, 33.3, 32.6,
30.54, 30.51, 30.50, 30.45, 30.43, 30.41, 30.37, 30.29, 30.25, 30.1, 26.9,
23.4, 14.8; HRMS (ESI-ion trap) m/z calcd for [C48H91NO13 + H
+]
890.6563, found 890.6569.
(2,6-Di-O-acetyl-3,4-diol-β-D-galactopyranosyl)-(1−4)-O-(1,2,3,6-
tetra-O-acetyl)-D-glucopyranoside (13). Method A: To a MeOH (3
mL) solution of compound 3 (41 mg, 0.06 mmol) was added Dowex
H+ resin (∼80 mg) until the pH = 2−3. The suspension was allowed
to stir at rt for 4.5 h until the starting material was completely
consumed. Next, the Dowex acidic resin was removed via filtration,
and the filtrate was concentrated to afford a viscous oil. The resulting
residue was immediately purified by flash column chromatography
(100% EA) to obtain compound 13 (30 mg, 92%) as a white foam.
Method B: To a MeOH solution of compound 3 (115 mg, 0.16
mmol) was added Pd(OH)2/C (20% Pd, 100 mg). The reaction
mixture was allowed to stir under H2 gas (1 atm) at rt for 0.5 h until
the starting material was completely consumed. Next, the Pd-catalyst
was removed by a short plug of MeOH-packed Celite. The filtrate was
concentrated to afford a viscous oil. The resulting residue was purified
by flash column chromatography (100% EA) to obtain compound 13
(85 mg, 91%) as a white foam. The product consisted of inseparable
α/β anomeric acetates, and the major β-anomer is reported: TLC
(100% EA) Rf 0.36;
1H NMR (600 MHz, CDCl3) δ 5.67 (d, J = 8.8
Hz, 1H, H-1), 5.23 (appt. t, J = 8.8 Hz, 1H, H-3), 5.07 (appt. t, J = 8.8
Hz, 1H, H-2), 4.81 (appt. t, J = 8.4 Hz, 1H, H-2′), 4.46 (d, J = 12.4 Hz,
1H, H-6a), 4.38-.34 (m, 2H, H-1′, H-6b), 4.28−4.22 (m, 1H, H-6′a),
4.22 (m, 1H, H-6′b), 3.84−3.77 (m, 3H, H-4, H-5, H-4′), 3.69−3.54
(m, 2H, H-3′, H-5′), 2.13 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H) 2.10 (s,
3H), 2.06 (s, 2H), 2.03 (s, 2H); 13C NMR (150 MHz, CDCl3) δ
171.9, 171.0, 170.4, 169.9, 169.5, 168.9, 100.5, 91.7, 75.6, 74.1, 73.7,
72.9, 72.4, 72.0, 70.4, 68.1, 62.1, 61.9, 20.9, 20.84, 20.82, 20.8, 20.76,
20.6; HRMS (ESI-ion trap) m/z calcd for [C24H34O17 + NH
+]
612.2134, found 612.2134.
(2,6-Di-O-acetyl-β-D-galactopyranosyl)-(1−4)-O-(1,2,3,6-tetra-O-
acetyl)-D-glucopyranoside (14). Method A: To a MeOH (3 mL)
solution of compound 2 (70 mg, 0.08 mmol) was added Pd(OH)2/C
(20% Pd, 50 mg). The reaction mixture was allowed to stir under H2
(1 atm) at rt for 0.5 h. Next, the reaction mixture was filtered through
a MeOH-packed Celite pad to remove the Pd catalyst, and the filtrate
was concentrated under reduced pressure. The resulting residue was
then dissolved in dry acetonitrile (2 mL) and treated with trimethyl
orthoacetate (32 μL, 0.25 mmol) and catalytic camphorsulfonic acid
(∼4 mg, 0.02 mmol). After 1 h, NEt3 (∼0.1 mL) was added to quench
the reaction, and the reaction mixture was concentrated under reduced
pressure. The resulting residue was then dissolved in CH2Cl2 (2 mL)
and treated with Ac2O (50 μL, 0.50 mmol), NEt3 (105 μL, 0.75
mmol) and catalytic DMAP (∼2 mg). After 0.5 h, the solvent was
evaporated, and the dry residue was treated with 80% AcOH(aq) at rt
with vigorous stirring for another 0.5 h. The reaction mixture was then
azeotroped with benzene to remove excess reagents, and the resulting
residue was purified using flash column chromatography (EA/Hex =
3/1 to 4/1) to afford compound 14 (52 mg, 95%) as a white foam.
Method B: To a MeOH (3 mL) solution of compound 3 (65 mg,
0.088 mmol) was added Pd(OH)2/C (20% Pd, 60 mg). The reaction
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mixture was allowed to stir under H2 (1 atm) at rt for 0.5 h. Next, the
reaction mixture was filtered through a MeOH-packed Celite pad to
remove the Pd catalyst, and the filtrate was concentrated under
reduced pressure. The resulting residue was then dissolved in dry ACN
(2 mL) and treated with trimethyl orthoacetate (35 μL, 0.26 mmol)
and catalytic CSA (∼4 mg, 0.02 mmol). After 1 h, NEt3 (∼0.1 mL)
was added to quench the reaction, and the reaction mixture was
concentrated under reduced pressure. The resulting residue was
treated with 80% AcOH(aq) at rt with vigorous stirring for another 0.5
h. The reaction mixture was then azeotroped with benzene to remove
the excess reagents, and the resulting residue was purified using flash
column chromatography (EA/Hex = 3/1 to 4/1) to afford compound
14 (57 mg, 98%) as a white foam. The product consisted of
inseparable α/β anomeric acetates, and the major β-anomer is
reported: TLC (EA/Hex = 2/1) Rf 0.28;
1H NMR (600 MHz, CDCl3)
δ 5.68 (d, J = 8.4 Hz, 1H, H-1), 5.30 (d, J = 2.9 Hz, 1H, H-4′), 5.24
(appt. t, J = 9.3 Hz, 1H, H-3), 5.06 (dd, J = 9.3, 8.4 Hz, 1H, H-2), 4.85
(dd, J = 10.0, 7.9 Hz, 1H, H-2′), 4.47 (dd, J = 12.1, 1.8 Hz, 1H, H-6a),
4.42 (d, J = 7.9 Hz, 1H, H-1′), 4.20 (dd, J = 12.1, 4.9 Hz, 1H, H-6b),
4.15−4.04 (m, 2H, H-6′ab), 3.86−3.73 (m, 4H, H-4, H-5, H-3′, H-5′),
2.46 (d, J = 6.3 Hz, 1H, OH), 2.18 (s, 3H), 2.13 (s, 3H), 2.12 (s, 3H),
2.10 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H); 13C NMR (150
MHz, CDCl3) δ 171.2, 170.7, 170.5, 170.4, 169.7, 169.5, 100.6, 91.6,
75.7, 73.6, 73.1, 72.5, 71.8, 71.0, 70.4, 69.1, 61.9, 61.4, 20.84, 20.81,
20.75, 20.73, 20.67, 20.5; HRMS (ESI-ion trap) m/z calcd for
[C26H36O18 + NH4
+] 654.2240, found 654.2289.
General Procedure for Constructing Globotriaose and
Isoglobotriaose (Table 1). To a 0 °C CH2Cl2 solution of compound
15 (conc. 0.1−0.2 M, 2.5 equiv) was added TMSI (2.8 equiv) under
argon atmosphere. After stirring for 30 min, the reaction mixture was
azeotroped with anhydrous benzene (5 mL × 3) and dried under a
high vacuum system for 1 h to afford the corresponding glycosyl iodide
as a light yellow foam. The iodide was then dissolved in CH2Cl2 (1
mL) under argon and cooled to −78 °C. In a separate flask, AgOTf
(3.2 equiv), acceptor (compound 12, 13, or 14; ∼0.10 mmol scale; 1.0
equiv) and activated 4 Å molecular sieves (∼200 mg) were allowed to
stir in a CH2Cl2 (2 mL) solution under argon atmosphere at rt for 30
min. The acceptor solution was then cooled to −78 °C, and the cooled
glycosyl iodide solution was transferred dropwisely to the acceptor
flask via cannula. After 4 h, the reaction mixture was gradually warmed
from −78 to −30 °C, diluted with EA (10 mL), and quenched by NEt3
(∼1 mL). The suspension was filtered through a well-packed Celite
pad and washed with EA (∼30 mL). The filtrate was washed with
saturated NaHCO3(aq) (20 mL × 1) and brine (20 mL × 2), dried over
anhydrous Na2SO4, and concentrated under reduced pressure. The
resulting residue was purified by gradient flash column chromatog-
raphy (EA/Hex) to obtain corresponding oligosaccharides (compound
16, 17, 18, or 19) as white foams.
(2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl)-(1−4)-O-(2,3,6-tri-
O-acetyl-β-O-D-galactopyranosyl)-(1−4)-O-1,2,3,6-tetra-O-acetyl-D-
glucopyranoside (16). Following the general procedure for
constructing the globotriaose, compound 15 (510 mg, 0.88 mmol)
and TMSI (142 μL, 0.97 mmol) were used for galactosyl iodide
formation. The forming iodide CH2Cl2 solution (1 mL) was then
cannulated to the CH2Cl2 solution (1.5 mL) of 4′-OH acceptor 12
(220 mg, 0.35 mmol) under the activation of AgOTf (270 mg, 1.05
mmol) at −78 to −30 °C for 4 h with the presence of activated 4 Å
molecular sieves (800 mg). After workup, the reaction mixture was
then purified by gradient flash column chromatography (EA/Hex = 2/
3 to 1/1) to obtain 16 (300 mg, 75%) as a white foam (Table 1, entry
1). The product consisted of inseparable α/β anomeric acetates, and
the major β-anomer is reported: TLC (EA/Hex = 1/1) Rf 0.43;
1H
NMR (800 MHz, CDCl3) δ 7.43−7.24 (m, 20H, ArH), 5.65 (d, J = 8.9
Hz, 1H, H-1), 5.20 (appt. t., J = 8.9 Hz, 1H, H-3), 5.13 (dd, J = 10.2,
7.9 Hz, 1H, H-2′), 5.04 (appt. t, J = 8.9 Hz, 1H, H-2), 4.92 (d, J = 12.0
Hz, 1H, PhCH), 4.86−4.80 (m, 2H, PhCH2), 4.76−4.73 (m, 3H, H-
1″, H-3′, PhCH), 4.67 (d, J = 12 Hz, 1H, PhCH), 4.56 (d, J = 12 Hz,
1H, PhCH), 4.50−4.40 (m, 4H, H-6a, H-6′ab, PhCH × 2), 4.39 (d, J
= 7.9 Hz, 1H, H-1′), 4.27 (dd, J = 9.0, 4.7 Hz, 1H, H-5″), 4.16 (s, 1H,
H-4″), 4.10 (dd, J = 12.3, 4.6 Hz, 1H, H-6b), 4.05 (m, 1H, H-2″), 3.97
(d, J = 2.3, 1H), 3.77 (appt. t, J = 8.9 Hz, 1H, H-4), 3.72 (dd, J = 10.0,
4.7 Hz, 1H, H-5), 3.64 (appt. t, J = 6.8 Hz, 1H, H-5′), 3.61 (appt. t, J =
8.6 Hz, 1H, H-6″a), 3.42 (dd, J = 8.6, 4.9 Hz, 1H, H-6″b), 2.11 (s,
3H), 2.09 (s, 3H), 2.04 (s, 6H), 2.03 (s, 3H), 2.02 (s, 3H), 1.86 (s,
3H), 1.85 (s, 3H); 13C NMR (200 MHz, CDCl3) δ 170.7, 170.4,
170.3, 169.8, 169.5, 168.9, 168.7, 138.8, 138.7, 138.1, 137.9, 128.4,
128.33, 128.30, 128.2, 128.15, 128.11, 128.0, 127.7, 127.6, 127.4,
127.36, 127.34, 101.4, 101.0, 91.7, 79.1, 76.0, 75.5, 75.3, 75.0, 74.6,
74.2, 73.6, 73.3, 72.8, 72.5, 72.3, 72.2, 70.3, 69.6, 69.4, 67.6, 61.7, 61.0,
20.84, 20.82, 20.6, 20.5; HRMS (ESI-ion trap) m/z calcd for
[C60H70O23 + Na
+] 1181.4200, found 1181.4241.
(2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl)-(1−3)-O-(2,6-di-
O-acetyl-β-O-D-galactopyranosyl)-(1−4)-O-1,2,3,6-tetra-O-acetyl-D-
glucopyranoside (17). Following the general procedure for
constructing the isoglobotriaose scaffold, compound 15 (183 mg,
0.32 mmol) and TMSI (50 μL, 0.36 mmol) were used for galactosyl
iodide formation. The CH2Cl2 solution (1.5 mL) of forming iodide
was then cannulated to the CH2Cl2 solution (1.5 mL) of 3′,4′-di-OH
acceptor 13 (75 mg, 0.13 mmol) under the activation of AgOTf (103
mg, 0.42 mmol) at −78 to −30 °C for 4 h with the presence of
activated 4 Å molecular sieves (300 mg). After workup, the reaction
mixture was then purified by flash column chromatography (EA/Hex
= 50:50) to obtain 17 (37 mg, 26%) as a white amorphous foam and
compound 18 (63 mg, 31%) as a colorless oil (Table 1, entry 3). The
product consisted of inseparable α/β anomeric acetates, and the major
β-anomer is reported: TLC (EA/Hex = 1/1) Rf 0.43;
1H NMR (800
MHz, CDCl3) δ 7.41−7.34 (m, 5H, ArH), 7.34−7.20 (m, 15H, ArH),
5.64 (d, J = 8.3 Hz, 1H, H-1), 5.21 (appt. t, J = 9.4 Hz, 1H, H-3),
5.06−5.03 (m, 2H, H-2, H-2′), 4.88 (d, J = 11.6 Hz, 1H, PhCH), 4.86
(d, J = 11.4, 1H, PhCH), 4.74 (s, 2H, PhCH2), 4.68 (d, J = 3.7 Hz, 1H,
H-1″), 4.63 (d, J = 11.6 Hz, 1H, PhCH), 4.52 (d, J = 11.4 Hz, 1H,
PhCH), 4.46−4.40 (m, 2H, H-6a, PhCH), 4.33 (d, J = 11.9 Hz, 1H,
PhCH), 4.30−4.24 (m, 3H, H-1′, H-6′ab), 4.15−4.09 (m, 1H, H-6b),
4.01 (dd, J = 9.6, 3.8 Hz, 1H, H-2″), 3.95−3.89 (m, 2H, H-4′, H-3″),
3.81−3.78 (m, 2H, H-4, H-5″), 3.76−3.69 (m, 2H, H-5, H-4′), 3.60−
3.55 (m, 2H, H-5′, H-3′), 3.43−3.36 (m, 2H, H-6″ab), 2.14 (s, 3H),
2.10 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.95 (s, 3H); 13C
NMR (200 MHz, CDCl3) δ 170.8, 170.4, 169.9, 169.6, 169.5, 168.9,
138.3, 137.6, 137.4, 128.6, 128.57, 128.46, 128.4, 128.3, 128.27,
128.24, 127.9, 127.8, 127.7, 127.66, 127.5, 100.4, 96.5, 91.7, 79.6, 78.5,
75.3, 74.9, 74.8, 74.7, 74.3, 73.7, 73.5, 72.9, 72.1, 71.9, 70.7, 70.4, 70.1,
68.8, 65.0, 63.1, 61.8, 20.9, 20.8, 20.7, 20.67, 20.63; HRMS (ESI-ion
trap) m/z calcd for [C58H68O22 + NH4
+] 1134.4540, found 1134.4445.
(2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl)-(1−3)-O-(2,3,6-tri-
O-acetyl-4-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-β-O-D-
galactopyranosyl)-(1−4)-O-1,2,3,6-tetra-O-acetyl-D-glucopyrano-
side (18). Compound 18 (63 mg, 31%) was obtained as a colorless oil
(Table 1, entry 3; see compound 17 and general procedure for
constructing isoglobotriaose for reaction and purification conditions).
The product consisted of inseparable α/β anomeric acetates, and the
major β-anomer is reported: TLC (EA/Hex = 1/1) Rf 0.63;
1H NMR
(600 MHz, methanol-d4) δ 5.71 (d, J = 8.3 Hz, 1H, H-1), 5.29−5.20
(m, 2H), 5.07 (appt. t, J = 8.9 Hz, 1H), 4.98−4.92 (m, 3H), 4.80 (d, J
= 11.2 Hz, 1H), 4.77−4.70 (m, 2H), 4.65 (d, J = 11.3 Hz, 2H), 4.59−
4.23 (m, 18H), 4.20 (d, J = 8.3 Hz, 1H), 4.13 (dd, J = 12.3, 5.1 Hz,
1H), 4.10−3.98 (m, 5H), 3.97−3.75 (m, 8H), 3.71−3.60 (m, 5H),
3.51 (appt. t, J = 8.8 Hz, 1H), 3.44−3.38 (m, 1H), 2.07 (s, 3H), 2.05
(s, 3H), 2.00 (s, 6H), 1.97 (s, 3H), 1.88 (s, 3H); 13C NMR (150 MHz,
methanol-d4) δ 172.5, 172.3, 171.5, 171.2, 171.1, 170.4, 140.5, 140.3,
140.23, 140.20, 140.0, 139.9, 139.6, 129.7, 129.4, 129.38, 129.32,
129.24, 129.21, 129.20, 129.16, 129.14, 128.9, 128.8, 128.61, 128.56,
128.53, 128.46, 128.41, 103.2, 102.2, 100.6, 92.9, 79.9, 79.8, 78.8, 78.4,
76.8, 76.8, 76.3, 76.1, 76.0, 74.9, 74.4, 74.2, 74.1, 73.2, 73.0, 71.9, 71.4,
70.8, 69.4, 65.3, 63.4, 49.4, 49.3, 49.1, 49.0, 48.9, 48.7, 48.6, 32.8, 23.7,
21.5, 21.2, 20.9, 20.7, 20.6, 20.5, 14.4; HRMS (ESI-ion trap) m/z calcd
for [C92H102O27 + NH4
+] 1656.6947, found 1656.6932.
(2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl)-(1−3)-O-(2,4,6-tri-
O-acetyl-β-O-D-galactopyranosyl)-(1−4)-O-1,2,3,6-tetra-O-acetyl-D-
glucopyranoside (19). Following the general procedure for
constructing the isoglobotriaose scaffold, compound 15 (75 mg, 0.13
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mmol) and TMSI (20 μL, 0.15 mmol) were used for galactosyl iodide
formation. The CH2Cl2 solution (1.5 mL) of the forming iodide was
then cannulated to the CH2Cl2 solution (1.5 mL) of 4′-OH acceptor
14 (33 mg, 0.05 mmol) under the activation of AgOTf (42 mg, 0.16
mmol) at −30 °C to rt for 24 h with the presence of activated 4 Å
molecular sieves (300 mg) and tetramethylurea (TMU, 20 μL, 0.16
mmol). After workup, the reaction mixture was then purified by flash
column chromatography (EA/Hex = 50:50) to obtain 19 (45 mg,
75%) as a white amorphous foam (Table 1, entry 5). The product
consisted of inseparable α/β anomeric acetates, and the major β-
anomer is reported: TLC (EA/Hex = 1/1) Rf 0.40;
1H NMR (600
MHz, CDCl3) δ 7.39−7.23 (m, 20H, ArH), 5.66 (d, J = 8.2 Hz, 1H, H-
1), 5.42 (d, J = 3.0 Hz, 1H, H-4′), 5.22 (appt. t, J = 9.0 Hz, 1H, H-3),
5.09 (dd, J = 10.1, 7.9 Hz, 1H, H-2′), 5.04−5.01 (m, 2H, H-2, H-1″),
4.90 (d, J = 11.4 Hz, 1H, PhCH), 4.81 (d, J = 11.8 Hz, 1H, PhCH),
4.71−4.67 (m, 2H, PhCH × 2), 4.63 (d, J = 11.6 Hz, 1H, PhCH),
4.50−4.47 (m, 2H, PhCH × 2), 4.42−4.37 (m, 2H, PhCH, H-6a),
4.31 (d, J = 7.9 Hz, 1H, H-1′), 4.10 (dd, J = 12.0, 5.1 Hz, 1H, H-6b),
4.07−4.01 (m, 2H, H-6′ab), 3.98 (dd, J = 10.0, 3.4 Hz, 1H, H-2″),
3.87−3.71 (m, 6H, H-4, H-3′, H-5′, H-3″, H-4″, H-5″), 3.66 (appt. t, iJ
= 6.7 Hz, 1H, H-5), 3.55−3.45 (m, 2H, H-6″ab), 2.09 (s, 3H), 2.08 (s,
3H), 2.07 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.92 (s, 3H), 1.81 (s,
3H); 13C NMR (150 MHz, CDCl3) δ 170.4, 170.3, 170.2, 169.6,
169.5, 168.8, 168.7, 138.7, 138.67, 138.61, 138.0, 128.4, 128.35, 128.2,
128.15, 128.13, 127.9, 127.7, 127.6, 127.56, 127.50, 127.4, 100.9, 95.1,
91.6, 78.4, 75.7, 75.2, 75.1, 74.8, 73.6, 73.3, 73.2, 73.0, 72.6, 71.1, 70.5,
69.9, 68.5, 64.8, 61.4, 20.8, 20.8, 20.7, 20.68, 20.66, 20.59, 20.4; HRMS
(ESI-ion trap) m/z calcd for [C60H70O23 + Na
+] 1181.4200, found
1181.4279.
(2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl)-(1−4)-O-(2,3,6-tri-
O-acetyl-β-O-D-galactopyranosyl)-(1−4)-O-1,2,3,6-tetra-O-acetyl-D-
glucopyranoside (per-O-Ac globotriaose, 20). To a MeOH (5 mL)
solution of compound 16 (186 mg, 0.16 mmol) was added Pd(OH)2/
C (20% Pd, 180 mg). The reaction mixture was allowed to stir under
H2 gas (1 atm) at rt for 1 h. Next, the reaction mixture was filtered
through a MeOH-packed Celite pad to remove the Pd catalyst, and the
filtrate was concentrated under reduced pressure. The resulting residue
was then dissolved in CH2Cl2 (4 mL) and treated with Ac2O (0.3 mL,
3.2 mmol), NEt3 (0.4 mL, 3.2 mmol) and catalytic DMAP (6 mg, 0.05
mmol). After stirring overnight, the reaction mixture was concentrated
under reduced pressure and purified using flash column chromatog-
raphy (EA/Hex = 2:1) to afford 20 (147 mg, 95%) as a white foam.
The product consisted of inseparable α/β anomeric acetates, and the
major β-anomer is reported: TLC (EA/Hex = 2/1) Rf 0.33;
1H NMR
(800 MHz, CDCl3) δ 5.68 (d, J = 8.3 Hz, 1H, H-1), 5.58 (d, J = 3.2
Hz, 1H, H-4″), 5.39 (dd, J = 11.0, 3.4 Hz, 1H, H-3″), 5.24 (appt. t, J =
9.2 Hz, 1H, H-3), 5.18 (dd, J = 11.0, 3.6 Hz, 1H, H-2″), 5.10 (dd, J =
10.8, 7.8 Hz, 1H, H-2′), 5.05 (dd, J = 9.2, 8.3 Hz, 1H, H-2), 4.98 (d, J
= 3.6 Hz, 1H, H-1″), 4.72 (dd, J = 10.8, 2.6 Hz, 1H, H-3′), 4.52−4.47
(m, 2H, H-1′, H-5″), 4.45−4.42 (m, 2H, H-6a, H-6′a), 4.20−4.08 (m,
4H, H-6b, H-6′b, H-6″ab), 4.01 (s, 1H, H-4′), 3.84 (dd, J = 19.8, 9.2
Hz, 1H, H-4), 3.79−3.75 (m, 2H, H-5, H-5′), 2.13 (s, 3H), 2.11 (s,
3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.06 (s,
3H), 2.05 (s, 3H), 2.03 (s, 3H), 1.98 (s, 3H); 13C NMR (200 MHz,
CDCl3) δ 170.6, 170.5, 170.4, 170.3, 170.0, 169.6, 169.5, 168.8, 168.7,
100.9, 99.6, 91.5, 75.8, 73.4, 72.9, 72.7, 71.8, 70.5, 68.8, 68.7, 67.8,
67.1, 67.0, 61.8, 61.3, 60.2, 20.9, 20.8, 20.7, 20.6, 20.59, 20.54, 20.4;
HRMS (ESI-ion trap) m/z calcd for [C40H54O27 + Na
+] 989.2745,
found 989.2771.
α-D-Galactopyranosyl-(1−4)-β-D-galactopyranosyl-(1−4)-D-glu-
copyranose (globotriaose, 21). To a MeOH solution of compound
16 (63 mg, 0.054 mmol) was added Pd(OH)2/C (20% Pd, 63 mg)
and stirred under H2 gas (1 atm) for 2 h. After the disappearance of
starting material on TLC, the Pd(OH)2/C was removed by passing
through a MeOH-packed Celite pad. The filtrate was concentrated and
redissolved in anhydrous MeOH (3 mL) followed by addition of
NaOMe/MeOH solution (25 wt %, 40 μL). Some white suspension
formed after 15 min, and H2O (1.0 mL) was added to dissolve the
suspension. The reaction mixture was stirred for another 15 min and
was acidified to pH = 6 by adding Dowex H+ resin. The solution was
filtered through a plug of C18 reverse-phrase silica gel and washed with
MeOH and water to remove the resin and desalt. The filtrate was
concentrated and lyophilized to afford compound 21 (27 mg, 99%) as
a white fluffy foam: TLC (EA/2-propanol/H2O = 2:2:1) Rf 0.22;
1H
NMR (800 MHz, D2O) δ 5.22 (d, J = 3.7 Hz, 0.4 H), 4.94 (d, J = 3.7
Hz, 1H), 4.66 (d, J = 8.0 Hz, 0.4 H), 4.50 (dd, J = 7.8, 1.7 Hz, 1H),
4.35 (s, 1H), 4.06−4.01 (m, 2H), 3.98−3.54 (m, 14H), 3.27 (appt. t, J
= 8.6 Hz, 0.4 H); 13C NMR (200 MHz, D2O) δ 103.90, 103.86, 101.0,
96.4, 92.4, 79.3, 79.2, 78.0, 75.5, 74.5, 72.8, 71.5, 70.8, 69.8, 69.6,
69.22, 69.20, 61.1, 61.0, 60.7, 60.6 (Assignment matches with
literature);64 HRMS (ESI0-ion trap) m/z calcd for [C18H32O16 +
NH4
+] 522.2029, found 522.2012.
(2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl)-(1−4)-O-(2,3,6-tri-
O-acetyl-β-O-D-galactopyranosyl)-(1−4)-O-1,2,3,6-tetra-O-acetyl-D-
glucopyranosyl iodide (22). In an oven-dried NMR tube, compound
20 (20 mg, 0.02 mmol) was added and dissolved in dry CDCl3 (0.2
mL). After TMSI (4 μL, 0.03 mmol) was introduced to the reaction
vessel, the reaction was kept and 0 °C and gradually warmed to rt over
4−5 h. The reaction was monitored by proton NMR until its
corresponding iodide (22) formed: in situ 1H NMR (800 MHz,
CDCl3) δ 6.90 (d, J = 4.3 Hz, 1H, H-1), 5.58 (d, J = 3.2 Hz, 1H, H-
4″), 5.45 (appt. t, J = 9.5 Hz, 1H, H-3), 5.39 (dd, J = 11.0, 3.2 Hz, 1H,
H-3″), 5.17 (dd, J = 11.0, 3.5 Hz, 1H, H-2″), 5.11 (dd, J = 10.8, 7.8
Hz, 1H, H-2′), 4.98 (d, J = 3.5 Hz, 1H, H-1″), 4.72 (dd, J = 10.8, 2.6
Hz, 1H, H-3′), 4.53 (d, J = 7.8 Hz, 1H, H-1′), 4.50−4.41 (m, 3H, H-
5″, H-6a, H-6′a), 4.20−4.07 (m, 5H, H-2, H-6b, H-6′b, H-6″ab), 4.01
(d, J = 1.8 Hz, 1H, H-4′), 3.98−3.95 (m, 1H, H-5), 3.89 (appt. t, J =
9.5 Hz, 1H, H-4), 3.78 (appt. t, J = 6.7 Hz, 1H, H-5′), 2.12 (s, 3H),
2.11 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H),
2.057 (s, 3H), 2.053 (s, 3H), 2.05 (s, 3H), 1.98 (s, 3H); in situ 13C
NMR (200 MHz, CDCl3) δ 170.7, 170.6, 170.5, 170.4, 170.3, 170.1,
169.8, 169.5, 169.2, 168.8, 100.7, 99.5, 75.5, 74.7, 72.8, 72.6, 71.8, 71.3,
70.4, 68.8, 67.8, 67.1, 66.9, 61.4, 61.0, 60.2, 20.9, 20.84, 20.80, 20.75,
20.72, 20.67, 20.64, 20.61, 20.58, 20.55.
(2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl)-(1−3)-O-(2,4,6-tri-
O-acetyl-β-O-D-galactopyranosyl)-(1−4)-O-1,2,3,6-tetra-O-acetyl-β-
D-glucopyranoside (per-O-Ac isoglobotriaose, 23). To a MeOH (5
mL) solution of compound 17 (32 mg, 0.03 mmol) was added
Pd(OH)2/C (20% Pd, 30 mg). The reaction mixture was allowed to
stir under H2 gas (1 atm) at rt for 1 h. Next, the reaction mixture was
filtered through a MeOH-packed Celite pad to remove the Pd catalyst,
and the filtrate was concentrated under reduced pressure. The
resulting residue was then dissolved in CH2Cl2 (2 mL) and treated
with Ac2O (0.3 mL, 3.2 mmol), NEt3 (0.4 mL, 3.2 mmol) and catalytic
DMAP (∼2 mg). After stirring for 3 h, the reaction mixture was
concentrated under reduced pressure and purified using flash column
chromatography (EA/Hex = 70:30) to afford 23 (23 mg, 85%) as a
white foam. The product consisted of inseparable α/β anomeric
acetates, and the major β-anomer is reported: TLC (EA/Hex = 70:30)
Rf 0.41;
1H NMR (800 MHz, CDCl3) δ 5.67 (d, J = 8.4 Hz, 1H, H-1),
5.45 (dd, J = 3.1, 1.4 Hz, 1H, H-4″), 5.32 (d, J = 2.4 Hz, 1H, H-4′),
5.27−5.21 (m, 3H, H-3, H-1″, H-2″), 5.16 (dd, J = 10.3, 7.9 Hz, 1H,
H-2′), 5.09 (dd, J = 10.9, 3.2 Hz, 1H, H-3″), 5.04 (dd, J = 9.4, 8.4 Hz,
1H, H-2), 4.46−4.38 (m, 2H, H-6a, H-1′), 4.22−4.01 (m, 6H, H-6b,
H-6′ab,, H-5″, H-6″ab), 3.87−3.74 (m, 4H, H-4, H-5, H-3′, H-5′),
2.16 (s, 3H), 2.14 (s, 3H), 2.13 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H),
2.07 (s, 3H), 2.061 (s, 3H), 2.057 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H),
1.95 (s, 3H); 13C NMR (200 MHz, CDCl3) δ 170.6, 170.5, 170.4,
170.3, 170.1, 169.9, 169.8, 169.7, 169.0, 168.8, 101.1, 93.5, 91.6, 75.5,
73.6, 72.9, 72.7, 70.9, 70.6, 69.7, 67.3, 66.9, 66.6, 64.7, 61.9, 61.3, 61.1,
21.0, 20.97, 20.93, 20.91, 20.88, 20.84, 20.77, 20.73, 20.6; HRMS (ESI-
ion trap) m/z calcd for [C40H54O27 + NH4
+] 984.3191, found
984.3215.
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